Bionano Genomics Inc (NASDAQ: BNGO) on Friday, soared 2.24% from the previous trading day, before settling in for the closing price of $0.22. Within the past 52 weeks, BNGO’s price has moved between $0.20 and $2.27.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 32.87% annually for the last half of the decade. The company achieved an average annual earnings per share of 77.19%. With a float of $101.34 million, this company’s outstanding shares have now reached $101.99 million.
In an organization with 344 employees, it is important to assess its efficiency. In terms of profitability, gross margin is -1.8%, operating margin of -324.25%, and the pretax margin is -407.35%.
Bionano Genomics Inc (BNGO) Insider Updates
Observing investor behavior towards Medical Instruments & Supplies industry stocks is more important than anything else. The insider ownership of Bionano Genomics Inc is 0.64%, while institutional ownership is 10.26%.
Bionano Genomics Inc (BNGO) Performance Highlights and Predictions
As on 9/30/2024, Multinational firm has announced its last quarter scores, in which it reported -0.96 earnings per share (EPS) for the period falling under the consensus outlook (set at -0.87) by -0.09. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.14 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 77.19% per share during the next fiscal year.
Bionano Genomics Inc (NASDAQ: BNGO) Trading Performance Indicators
Bionano Genomics Inc (BNGO) is currently performing well based on its current performance indicators. A quick ratio of 0.99 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 0.70.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.31, a number that is poised to hit -0.13 in the next quarter and is forecasted to reach -0.31 in one year’s time.
Technical Analysis of Bionano Genomics Inc (BNGO)
Let’s dig in a bit further. During the last 5-days, its volume was 3.48 million. That was better than the volume of 1.81 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 19.54%. Additionally, its Average True Range was 0.03.
During the past 100 days, Bionano Genomics Inc’s (BNGO) raw stochastic average was set at 4.91%, which indicates a significant decrease from 21.28% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 69.54% in the past 14 days, which was lower than the 86.44% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.3405, while its 200-day Moving Average is $0.7116. However, in the short run, Bionano Genomics Inc’s stock first resistance to watch stands at $0.2284. Second resistance stands at $0.2328. The third major resistance level sits at $0.2395. If the price goes on to break the first support level at $0.2173, it is likely to go to the next support level at $0.2106. Assuming the price breaks the second support level, the third support level stands at $0.2062.
Bionano Genomics Inc (NASDAQ: BNGO) Key Stats
Market capitalization of the company is 23.36 million based on 101,993K outstanding shares. Right now, sales total 36,120 K and income totals -232,490 K. The company made 6,070 K in profit during its latest quarter, and -44,250 K in sales during its previous quarter.
